Long-Term Cardiovascular Effects of COVID-19

In many places worldwide, the worst part of the pandemic is still to come. Meanwhile, in other areas, the number of cases is rising again. In this context, the long-term effects of COVID-19 are starting to show.

COVID-19 efectos cardiovasculares

Many believe this is not a current issue, but it will definitely be a problem in the future.

It is paramount to detect cardiovascular morbidities and complications in order to mitigate active infections. These include myocarditis, infarction, stroke, venous thromboembolism and multisystem inflammatory syndrome in children.

There is little information about what happens after the acute phase; however, recent publications have begun to shed some light on its impact.

The work done by Dr. Puntmann et al. showed that 78% of adult patients who recovered from COVID-19 presented some type of myocardial involvement. Said involvement was, in most cases, an inflammation diagnosed by magnetic resonance imaging and positive ultra-sensitive troponin. The results derived from magnetic resonance imaging differ from those from autopsies. In the latter, the evidence of myocarditis from COVID-19 is up to 10x lower than in magnetic resonance imaging.


Read also: The Key We Are Overlooking in Peripheral Vascular Disease.


This difference between imaging and anatomical pathology may possibly be caused by overinterpretation of the former, which could be mimicking inflammation. Physiological and technical variables might play a role.

Other coronaviruses, such as SARS and MERS, caused myocarditis in extremely rare cases. Unless this new coronavirus SARS-CoV-2 is functionally different from its predecessors, we should not expect long-term cardiac inflammation.

This pandemic proven the importance of anatomical pathology studies. Quality autopsies made it possible to calibrate clinical, radiological, and laboratory findings during the course of the infection.


Read also: Dietary Supplements and Diets Show No Impact on Cardiovascular Risk.


These autopsies mostly showed that the large number of pathological findings in the cardiovascular system were secondary to inflammation and not directly caused by the virus.

Lastly, the public health risk caused by COVID-19 should be balanced with other more individual aspects of health, such as physical, mental, and emotional wellbeing.

CIRCULATIONAHA-120-051362free

Título original: An Urgent Need for Studies of the Late Effects of SARS-CoV-2 on the Cardiovascular System.

Referencia: Joseph J. Maleszewski et al. Circulation. 2020 Sep 24. Online before print. DOI: 10.1161/CIRCULATIONAHA.120.051362.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

TCT 2024 | Use of Drug-Coated Balloons for Side Branch Treatment in Provisional Stenting

In some cases, treating coronary bifurcations with provisional stenting requires side branch stenting, which may lead to suboptimal outcomes. Drug-coated balloons (DCBs) have emerged...

TCT 2024 | Use of Artificial Intelligence for Patients with Suspected Coronary Artery Disease

The current approach to chest pain mainly focuses on symptom characteristics, conducting functional tests for ischemia assessment. However, several randomized clinical trials have shown...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...